БУТТИНИ Мануэль (US),ЧЭНЬ Мин (US),ГАРДАИ Шира (US)
申请号：
RU2014153675
公开号：
RU2014153675A
申请日:
2013.06.18
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method for treating a patient who has been diagnosed with Alzheimers middle or last stage, comprising administering to the patient an effective regime of an antibody that binds to an epitope within residues 12-43 Αβ and preferably binds with compact plaques in comparison with diffuse blyashkami.2. A method according to Claim. 1, wherein the patient has been diagnosed with Alzheimers medium stadii.3. A method according to Claim. 1, wherein the patient has been diagnosed with Alzheimers last stadii.4. A method according to Claim. 1, wherein the antibody is characterized by the specificity for epitope central Αβ.5. A method according to claim. 4, wherein the antibody is the antibody 266 or a chimeric, humanized or venirovannuyu form 15S11 antibody or a chimeric, humanized or venirovannuyu form or antibody 22D12 or a chimeric, humanized or venirovannuyu formu.6. . A method according to claim 5, wherein the antibody comprises three complementarity determining region light chain variable region (CDR), wherein CDR L1 comprises amino acid sequence according to SEQ ID NO: 4, CDR L2 comprises an amino acid sequence according to SEQ ID NO: 5 and CDR L3 comprises an amino acid sequence according to SEQ ID NO: 6, and three CDR variable region of a heavy chain wherein CDR H1 comprises the amino acid sequence according to SEQ ID NO: 7, CDR H2 comprises an amino acid sequence according to SEQ ID NO: 8 and CDR-H3 comprises amino acid th sequence according to SEQ ID NO: 9.7. . A method according to claim 5, wherein the antibody comprises three CDR variable region of a light chain wherein CDR L1 comprises the amino acid sequence of residues 24-39 SEQ ID NO: 14, CDR L2 comprises the amino acid sequence of residues 55-61 SEQ ID NO: 14, and CDR L3 comprises the amino acid
